AAPL   373.89 (+2.69%)
MSFT   210.42 (+2.02%)
FB   238.67 (+2.25%)
GOOGL   1,501.61 (+2.16%)
AMZN   3,009.00 (+4.11%)
NVDA   394.61 (+2.63%)
CGC   16.80 (+2.13%)
BABA   238.26 (+6.56%)
MU   50.91 (+2.17%)
GE   6.91 (+1.32%)
TSLA   1,323.69 (+9.52%)
AMD   53.18 (+1.59%)
T   30.28 (+0.67%)
ACB   12.29 (+0.16%)
F   6.14 (+1.32%)
GILD   77.05 (+0.92%)
DIS   113.46 (+1.14%)
BAC   23.48 (+0.82%)
NFLX   497.50 (+4.32%)
BA   182.02 (+0.67%)
AAPL   373.89 (+2.69%)
MSFT   210.42 (+2.02%)
FB   238.67 (+2.25%)
GOOGL   1,501.61 (+2.16%)
AMZN   3,009.00 (+4.11%)
NVDA   394.61 (+2.63%)
CGC   16.80 (+2.13%)
BABA   238.26 (+6.56%)
MU   50.91 (+2.17%)
GE   6.91 (+1.32%)
TSLA   1,323.69 (+9.52%)
AMD   53.18 (+1.59%)
T   30.28 (+0.67%)
ACB   12.29 (+0.16%)
F   6.14 (+1.32%)
GILD   77.05 (+0.92%)
DIS   113.46 (+1.14%)
BAC   23.48 (+0.82%)
NFLX   497.50 (+4.32%)
BA   182.02 (+0.67%)
AAPL   373.89 (+2.69%)
MSFT   210.42 (+2.02%)
FB   238.67 (+2.25%)
GOOGL   1,501.61 (+2.16%)
AMZN   3,009.00 (+4.11%)
NVDA   394.61 (+2.63%)
CGC   16.80 (+2.13%)
BABA   238.26 (+6.56%)
MU   50.91 (+2.17%)
GE   6.91 (+1.32%)
TSLA   1,323.69 (+9.52%)
AMD   53.18 (+1.59%)
T   30.28 (+0.67%)
ACB   12.29 (+0.16%)
F   6.14 (+1.32%)
GILD   77.05 (+0.92%)
DIS   113.46 (+1.14%)
BAC   23.48 (+0.82%)
NFLX   497.50 (+4.32%)
BA   182.02 (+0.67%)
AAPL   373.89 (+2.69%)
MSFT   210.42 (+2.02%)
FB   238.67 (+2.25%)
GOOGL   1,501.61 (+2.16%)
AMZN   3,009.00 (+4.11%)
NVDA   394.61 (+2.63%)
CGC   16.80 (+2.13%)
BABA   238.26 (+6.56%)
MU   50.91 (+2.17%)
GE   6.91 (+1.32%)
TSLA   1,323.69 (+9.52%)
AMD   53.18 (+1.59%)
T   30.28 (+0.67%)
ACB   12.29 (+0.16%)
F   6.14 (+1.32%)
GILD   77.05 (+0.92%)
DIS   113.46 (+1.14%)
BAC   23.48 (+0.82%)
NFLX   497.50 (+4.32%)
BA   182.02 (+0.67%)
Log in

NYSE:BDXBecton Dickinson and Stock Price, Forecast & News

$253.33
+8.30 (+3.39 %)
(As of 07/6/2020 12:11 PM ET)
Add
Compare
Today's Range
$247.74
Now: $253.33
$256.00
50-Day Range
$228.94
MA: $240.94
$264.77
52-Week Range
$197.75
Now: $253.33
$286.72
Volume39,165 shs
Average Volume1.95 million shs
Market Capitalization$68.70 billion
P/E Ratio76.30
Dividend Yield1.29%
Beta0.93
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, thoracic and abdominal drainage, and surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Read More
Becton Dickinson and logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.3Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.90 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP07588710
Phone201-847-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.29 billion
Cash Flow$21.47 per share
Book Value$78.08 per share

Profitability

Net Income$1.23 billion

Miscellaneous

Employees70,093
Market Cap$68.70 billion
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable

Receive BDX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.

Becton Dickinson and (NYSE:BDX) Frequently Asked Questions

How has Becton Dickinson and's stock been impacted by COVID-19 (Coronavirus)?

Becton Dickinson and's stock was trading at $231.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BDX stock has increased by 9.3% and is now trading at $253.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Becton Dickinson and?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton Dickinson and in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Becton Dickinson and.

When is Becton Dickinson and's next earnings date?

Becton Dickinson and is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Becton Dickinson and.

How were Becton Dickinson and's earnings last quarter?

Becton Dickinson and Co (NYSE:BDX) issued its quarterly earnings data on Thursday, May, 7th. The medical instruments supplier reported $2.55 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.32 by $0.23. The medical instruments supplier had revenue of $4.25 billion for the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a net margin of 6.10% and a return on equity of 15.75%. The business's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.59 EPS. View Becton Dickinson and's earnings history.

How often does Becton Dickinson and pay dividends? What is the dividend yield for Becton Dickinson and?

Becton Dickinson and declared a quarterly dividend on Tuesday, April 28th. Shareholders of record on Tuesday, June 9th will be given a dividend of $0.79 per share on Tuesday, June 30th. This represents a $3.16 annualized dividend and a dividend yield of 1.25%. The ex-dividend date of this dividend is Monday, June 8th. View Becton Dickinson and's dividend history.

What price target have analysts set for BDX?

15 Wall Street analysts have issued 1-year price targets for Becton Dickinson and's stock. Their forecasts range from $248.00 to $300.00. On average, they expect Becton Dickinson and's stock price to reach $273.80 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price. View analysts' price targets for Becton Dickinson and.

Has Becton Dickinson and been receiving favorable news coverage?

News coverage about BDX stock has trended negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Becton Dickinson and earned a news impact score of -2.1 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Becton Dickinson and.

Who are some of Becton Dickinson and's key competitors?

What other stocks do shareholders of Becton Dickinson and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Becton Dickinson and investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), Abbott Laboratories (ABT), AT&T (T), Visa (V), AbbVie (ABBV), Verizon Communications (VZ), Cisco Systems (CSCO) and Chevron (CVX).

Who are Becton Dickinson and's key executives?

Becton Dickinson and's management team includes the following people:
  • Mr. Vincent A. Forlenza, Chairman & CEO (Age 66)
  • Mr. Thomas E. Polen Jr., Pres & COO (Age 46)
  • Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 62)
  • Mr. Samrat S. Khichi, Exec. VP & Gen. Counsel (Age 52)
  • Mr. Patrick K. Kaltenbach, Exec. VP & Pres of the Life Sciences Segment (Age 56)

What is Becton Dickinson and's stock symbol?

Becton Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

Who are Becton Dickinson and's major shareholders?

Becton Dickinson and's stock is owned by a variety of retail and institutional investors. Top institutional investors include Cacti Asset Management LLC (0.07%), Confluence Investment Management LLC (0.04%), Gantzert Investment Co. LLC ADV (0.00%), Park National Corp OH (0.00%), M&R Capital Management Inc. (0.00%) and Orrstown Financial Services Inc. (0.00%). Company insiders that own Becton Dickinson and stock include Alexandre Conroy, Betty D Larson, Catherine M Burzik, Charles R Bodner, Claire Fraser, James C Lim, James W Borzi, Patrick Kaltenbach, Ribo Alberto Mas, Roland Goette, Samrat S Khichi, Simon D Campion, Thomas E Polen Jr, Thomas J Spoerel, Timothy M Ring and Vincent A Forlenza. View institutional ownership trends for Becton Dickinson and.

Which major investors are selling Becton Dickinson and stock?

BDX stock was sold by a variety of institutional investors in the last quarter, including Cacti Asset Management LLC, M&R Capital Management Inc., Confluence Investment Management LLC, Thomasville National Bank, Gantzert Investment Co. LLC ADV, Park National Corp OH, and Orrstown Financial Services Inc.. Company insiders that have sold Becton Dickinson and company stock in the last year include Alexandre Conroy, Charles R Bodner, Claire Fraser, James C Lim, Patrick Kaltenbach, Ribo Alberto Mas, Roland Goette, Simon D Campion, Thomas J Spoerel, and Vincent A Forlenza. View insider buying and selling activity for Becton Dickinson and.

Which major investors are buying Becton Dickinson and stock?

BDX stock was purchased by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC. View insider buying and selling activity for Becton Dickinson and.

How do I buy shares of Becton Dickinson and?

Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Becton Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $253.43.

How big of a company is Becton Dickinson and?

Becton Dickinson and has a market capitalization of $68.72 billion and generates $17.29 billion in revenue each year. The medical instruments supplier earns $1.23 billion in net income (profit) each year or $11.68 on an earnings per share basis. Becton Dickinson and employs 70,093 workers across the globe.

What is Becton Dickinson and's official website?

The official website for Becton Dickinson and is www.bd.com.

How can I contact Becton Dickinson and?

Becton Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.